TERAPI FARMAKOLOGI PADA WANITA HAMIL YANG TERINFEKSI SARS-COV-2

Laila Nur Azizah; Yusticia Katar; Ariadi Ariadi

doi:10.55681/sentri.v3i7.3162

Authors

Laila Nur Azizah Universitas Andalas
Yusticia Katar Universitas Andalas
Ariadi Universitas Andalas

DOI:

https://doi.org/10.55681/sentri.v3i7.3162

Keywords:

terapi, Wanita hamil, sars cov-2

Abstract

COVID-19 is a new disease caused by a new strain of coronavirus, SARS-CoV-2 since the end of 2019. This pandemic is still ongoing and study about new evidences on etiopathogenesis, diagnosis, and therapy are updated daily. At this time, there there isn't any yet evidence to recommend specific COVID-19 therapies for either the pregnant or non-pregnant groups of women. RCTs and large-scale clinical trials of COVID-19 drugs are still ongoing.. This literature study is a narrative review that explores nine primary research literature on available pharmacological treatment options in pregnant women infected with SARS-CoV-2 through the Pubmed and ScienceDirect databases based on established inclusion and exclusion criteria. The most common types of therapy are: Remdesivir (Antivirus), Lopinavir/ritonavir (Antivirus); Hydroxychloroquine (Antimalaria); Ceftriaxone (Antibiotic); and Dexamethasone (Corticosteroid). The maternal mortality rate is 8.8% (9 from 102 mother) and for the infant is 10.7% (11 from 103 infant). While the cure rate is 91.7% (93 from 102 participants). The highest number of pregnant women infected with SARS-CoV-2 were cesarean delivery, preterm delivery, and increased ALT and AST values. The most common neonatal outcome is the incidence of LBW

Downloads

Download data is not yet available.

References

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [Diakses pada 9 Februari 2022]. Available from: https://covid19.who.int/

Peta Sebaran | Covid19.go.id [Internet]. [Diakses pada 9 Februari 2022]. Available from: https://covid19.go.id/peta-sebaran

WEBSITE CORONA SUMBAR [Internet]. [Diakses pada 9 Februari 2022]. Available from: https://corona.sumbarprov.go.id/

Prevalence of COVID-19 in pregnant and postnatal women - University of Birmingham [Internet]. [Diakses pada 9 Februari 2022]. Available from: https://www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/about/prevalence.aspx

POGI. Rekomendadi POGI Terkait Melonjaknya Kasus Ibu Hamil dengan Covid-19 dan Perlindungan Terhadap Tenaga Kesehatan. Vol. 4247608. (2021). p. 5.

Farnas H, Farnas H, Sriyanti R. Mode Of Delivery Does Not Correlate Fetal Outcome In Pregnancy With Covid-19 At Dr. M. Djamil Hospital Padang. Andalas Obstet Gynecol J [Internet]. (Feb 19, 2022) [cited 2022 Apr 17];6(1):42–9.

Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int J Gynaecol Obstet [Internet]. (Jun 1,2020);149(3):273–86.

Cunningham F.G., Leveno, K.J., Bloom, S.L.; Hauth J. Williams obstetrics. 25nd ed. 25nd ed. united stated: McGraw-Hill Education (2018).

Chen R, Zhang S, Su S, Ye H, Shu H. Interactions Between Specific Immune Status of Pregnant Women and SARS-CoV-2 Infection. Front Cell Infect Microbiol (2021) Aug 12;11:753.

Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, et al. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis [Internet]. (Jul 1,2020);39(7):1209–20.

Aziz MA et al. Rekomendasi Penanganan Infeksi Virus Corona (Covid-19) Pada Maternal (Hamil, Bersalin Dan Nifas) Revisi 2. Pokja Infeksi Saluran Reproduksi Perkumpulan Obstetri dan Ginekologi Indonesia Tahun 2020 [Internet] (2020);3–15. Tersedia di: https://pogi.or.id/publish/rekomendasi-penanganan-infeksi-virus-corona-covid-19-pada-maternal/

Vogel JP, Tendal B, Giles M, Whitehead C, Burton W, Chakraborty S, et al. Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. Aust New Zeal J Obstet Gynaecol. (Dec 1,2020);60(6):840–51.

Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 in pregnant women: a report based on 116 cases. Am J Obstet Gynecol [Internet] (Jul 1,2020) [;223(1):111.e1.

Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, Arian SE, et al. Maternal death due to COVID-19. Am J Obstet Gynecol [Internet] (Jul 1,2020);223(1):109.e1.

Prawirohardjo sarwono. Ilmu Kebidanan. PT Bustaka sarwono prawihardjo (2016).

Prof. Dr. Ida Bagus Gde Manuaba. Pengantar Kuliah Obstetri. Penerbit Buku Kedokteran. jakarta: EGC (2012).

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med [Internet] (Jun 11,2020);382(24):2327–36.

BPOM. Informatorium obat COVID-19 di Indonesia. BPOM RI. jakarta: BPOM RI (2020).

Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. (May 1,2018);153:85–94.

Gunawan sulistia gan. FARMAKOLOGI DAN TERAPI. edisi 6. jakarta: penerbit FKUI (2016).

LL B, R H-D, BJ K. Goodman & Gilman’s: the pharmacological basis of therapeutics. 13th ed. New york: McGraw-Hill Education (2018).

Yuan Z, Zhang LZ, Li B, Chung HT, Jiang JX, Chiang JY, et al. Investigation of echocardiographic characteristics and predictors for persistent defects of patent foramen ovale or patent ductus arteriosus in Chinese newborns. Biomed J [Internet]. (Apr 1,2021);44(2):209–16.